10 results about "Vinblastine" patented technology

The invention relates to the technical field of biological medicine, in particular to application of a creatine related gene detection reagent in preparation of breast cancer prognosis products. The creatine related gene is an IGFBP1 gene and / or a TBC1D4 gene. According to the method, the expression levels of IGFBP1 and TBC1D4 genes in breast cancer patient samples are detected, a risk score is calculated by using a random survival forest (RSF) model, and the one-year, two-year and three-year survival rates of breast cancer patients are accurately predicted according to the risk score result. Meanwhile, the invention proves that IGFBP1 and TBC1D4 genes can be used as potential targets for breast cancer treatment, the IGFBP1 and fulvestrant as well as the TBC1D4 and vinblastine have stable binding capacity, and a new basis is provided for selection of individualized treatment medicines for breast cancer.

The application discloses a Catharanthus roseus EIN3-EILs transcription factor and application thereof, relates to the field of biotechnology, and the nucleotide sequence of the transcription factor CrEIN3 is shown as SEQ ID NO:1, and the protein coding sequence is shown as SEQ ID NO:2. The overexpression method is as follows: cloning the Catharanthus roseus CrEIN3 gene; constructing an overexpression vector; obtaining an agrobacterium engineering strain through agrobacterium mediation; and transiently transforming the Catharanthus roseus petals. The Catharanthus roseus EIN3-EILs transcription factor CrEIN3 is applied to increasing the content of vinblastine in the Catharanthus roseus. Through transient overexpression of CrEIN3 in the Catharanthus roseus petals, the synthesis of vinblastine in the Catharanthus roseus petals can be remarkably improved, and this has important significance for efficient production of vinblastine in the Catharanthus roseus.

The application discloses a vinblastine synthase, an encoding gene thereof and an application, and belongs to the technical field of genetic engineering. By using transcriptome data of Vinca minor, a 2OGD enzyme, namely, vinblastine synthase Vm15G000668, is screened and obtained, and in-vitro purification finds that the vinblastine synthase Vm15G000668 can specifically catalyze conversion of longchun dimethylbiguanide into vinblastine, and a key catalytic step of vinblastine biosynthesis is analyzed. The application provides a high-efficiency and specific vinblastine synthetic biocatalyst, and provides technical support for large-scale and green preparation of vinblastine.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The invention belongs to the technical field of karyotype analysis of chromosomes, and particularly relates to a cell pretreatment solution for karyotype analysis and preparation of chromosomes and application of the cell pretreatment solution. The cell pretreatment solution comprises the following components: 15 mmol / L Hepes buffer solution with the pH value of 7.2-7.6, 0.08-1.2 [mu] g / mL of vinblastine, 0.1-0.5 v / v% of Triton X-100 and 1-2 mmol / L of EDTA (Ethylene Diamine Tetraacetic Acid), and is a cell pretreatment solution with low toxicity, better dyeing effect and good cell type universality. When the cell pretreatment liquid is used for preparing a chromosome specimen, the preparation time is remarkably shortened, not only can more metaphase cell division phases be obtained, but also the proportion of the division phases capable of being used for chromosome analysis is greater than 83%, and the efficiency of karyotype analysis is remarkably improved. Meanwhile, the prepared chromosome specimen is clear in structure number, good in form, high in dispersity and few in background impurities, and the accuracy of chromosome karyotype analysis is remarkably improved.

A compound as shown in general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and the use thereof in cancer-related diseases such as acute myeloid leukemia. The synthesized vinblastine derivative has an antiproliferative activity against acute myeloid leukemia cancer cells that is significantly superior to that of vinblastine, can be used as a toxin molecule in the development of antibody-drug conjugates, and has a great anti-tumor effect.

Disclosed is a method for treating a condition, which includes the steps of: selecting a patient for treatment who has the condition; administering to the patient at least one active pharmaceutical ingredient (API); and administering to the patient at least one metal complex represented by formula (I):including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof. Also disclosed is a composition for conducting the method, which includes: at least one API selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir; and at least one metal complex effective to potentiate an efficacy of the API to treat the condition, wherein the at least one metal complex is represented by formula (I), including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof.

The application discloses a method for improving vinblastine content in Catharanthus roseus based on EIN3 / EILs transcription factor CrEIL1 and a method for determining the vinblastine content. According to the method, the CrEIL1 gene of the Catharanthus roseus is cloned, a pLB-CrEIL1 plasmid vector is constructed, the CrEIL1 overexpression vector is constructed by using the pLB-CrEIL1 plasmid vector, and the CrEIL1 overexpression vector is used to mediate the overexpression of CrEIL1 in the Catharanthus roseus by means of Agrobacterium tumefaciens, so that the vinblastine yield in the Catharanthus roseus can be improved at low cost, in an environment-friendly and reliable manner.

The application provides an exosome composition for reducing side effects of chemotherapy treatment and a preparation method thereof, and belongs to the technical field of medicines. Methotrexate, vinblastine and daunorubicin are prepared into a co-crystal, loaded on UiO-66-NH2 connected with RGD, loaded on exosomes, and embedded in an acrylic acid, traditional Chinese medicine polysaccharide and pullulan compound to obtain a sustained-release high half-life exosome system, which is uniformly mixed with D-ribose, yeast-beta glucan and glutathione to obtain the exosome composition for reducing side effects of chemotherapy treatment. The traditional Chinese medicine polysaccharide is traditional Chinese medicine polysaccharide obtained by boiling water extraction and ethanol precipitation of radix codonopsis, angelica, polygonatum sibiricum and dendrobium officinale. The exosome composition for reducing side effects of chemotherapy treatment is prepared, drug resistance of tumor cells is reduced, drug efficacy is improved, side reactions after chemotherapy are reduced, the effect of targeted slow release of drugs is achieved, and the exosome composition has a wide application prospect.